22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
15:48 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology; inflammation

INDICATION: Stroke; shock/trauma Patient and mouse studies suggest inhibiting CCR5 could help treat stroke and traumatic brain injury (TBI). In stroke patients, the absence of a loss-of-function mutant CCR5 allele was associated with the severity...
20:43 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

MacroGenics' margetuximab shows survival benefit in Phase III readout

MacroGenics Inc. (NASDAQ:MGNX) said Feb. 6 that margetuximab led to a survival benefit vs. Herceptin trastuzumab in the Phase III SOPHIA trial to treat HER2-positive metastatic breast cancer. MacroGenics is planning a BLA submission next...
20:16 , Feb 7, 2019 |  BC Innovations  |  Translation in Brief

Driving for rodents

A gene drive-like system from a UCSD team could bring the creation of rodent models of multigenic diseases within easy reach of biotechs by cutting the costs associated with making them. Generating rodent models of...
15:28 , Feb 6, 2019 |  BC Extra  |  Clinical News

Big gain for MacroGenics after breast cancer readout

MacroGenics Inc. (NASDAQ:MGNX) shares leapt Wednesday after the company said margetuximab led to a survival benefit vs. Herceptin trastuzumab in the Phase III SOPHIA trial to treat HER2-positive metastatic breast cancer. MacroGenics is planning a...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
03:36 , Jan 4, 2019 |  BC Innovations  |  Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
07:01 , Dec 18, 2018 |  BC Extra  |  Tools & Techniques

Gritstone showcases mass spec-based neoantigen discovery platform

Gritstone Oncology Inc. (NASDAQ:GRTS) unveiled the inner workings of its mass spectrometry-based neoantigen identification platform, EDGE, in a Nature Biotechnology study published Monday. Results from the paper suggest building a machine-learning algorithm based on human...
14:42 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies identified a pyridocarbazole-based inhibitor of disease-associated hairpin forms of GGGGCC repeat expansions in C9orf72 that could help treat ALS. In HEK cells, an optimized version of a...
03:31 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...